Efficacy and safety of riociguat replacing PDE-5is for patients with pulmonary arterial hypertension: A systematic review and meta-analysis

Introduction: Pulmonary arterial hypertension (PAH) is a rare and progressive disease. Some patients treated with phosphodiesterase type 5 inhibitors (PDE-5is) fail to reach treatment goals. As a novel soluble guanylate cyclase agonist, riociguat acts on the same pathway as PDE-5is but functions via...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yu-Yang, Qu, Yi-Yang, Wang, Shang, Luo, Ci-Jun, Qiu, Hong-Ling, Li, Hui-Ting, Yuan, Ping, Wang, Lan, Li, Jin-Ling, Jiang, Rong, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909097/
https://www.ncbi.nlm.nih.gov/pubmed/36778016
http://dx.doi.org/10.3389/fphar.2023.1052546

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909097/
https://www.ncbi.nlm.nih.gov/pubmed/36778016
http://dx.doi.org/10.3389/fphar.2023.1052546

Ejemplares similares